Stockscreener 앱 받기
49.64
0.16%
-0.08
시장 영업 전:
49.90
0.26
+0.52%
전일 마감가:
$49.72
열려 있는:
$49.91
하루 거래량:
2.08M
Relative Volume:
0.60
시가총액:
$22.06B
수익:
$2.38B
순이익/손실:
$1.32B
주가수익비율:
27.88
EPS:
1.7806
순현금흐름:
$897.24M
1주 성능:
+2.39%
1개월 성능:
+8.84%
6개월 성능:
+34.71%
1년 성능:
+56.64%
1일 변동 폭
$49.16
$49.93
1주일 범위
$48.35
$50.08
52주 변동 폭
$31.58
$50.08
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
49.64 | 22.06B | 2.38B | 1.32B | 897.24M | 1.7806 |
VRTX
Vertex Pharmaceuticals Inc
|
435.10 | 110.67B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
766.02 | 80.98B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
787.95 | 49.00B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.79 | 41.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.81 | 33.28B | 5.36B | 287.73M | 924.18M | 2.5229 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma PLC $RPRX Shares Purchased by Torray Investment Partners LLC - MarketBeat
Precision Trading with Royalty Pharma Plc (RPRX) Risk Zones - Stock Traders Daily
3 Unpopular Stocks We’re Skeptical Of - Yahoo Finance
Ruffer LLP Has $3.50 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation - The Manila Times
A new $1 million prize will honor scientists who turn discoveries into drugs - Stock Titan
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
UBS raises Royalty Pharma stock price target on biopharma catalysts By Investing.com - Investing.com UK
Royalty Pharma (RPRX) PT Raised to $57 at UBS - StreetInsider
Royalty Pharma Approves Dividend and Expands J&J Research Funding - HarianBasis.co
Is It Too Late To Consider Royalty Pharma (RPRX) After Strong 57% One Year Rally? - Sahm
Royalty Pharma declares $0.235 dividend - MSN
Royalty Pharma Plc Hits New 52-Week High of USD 50.00 - Markets Mojo
Royalty Pharma Plc (RPRX): Investor Outlook With A Promising 3.56% Potential Upside - DirectorsTalk Interviews
Why Royalty Pharma Plc (RPRX) is One of the Most Undervalued Biotech Stocks to Buy Right Now - Yahoo Finance
Moran Wealth Management LLC Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
KBC Group NV Trims Holdings in Royalty Pharma PLC $RPRX - MarketBeat
5 Most Undervalued Biotech Stocks to Buy Right Now - Insider Monkey
Royalty Pharma stock hits 52-week high at $49.07 By Investing.com - Investing.com India
Royalty Pharma declares $0.235 quarterly dividend By Investing.com - Investing.com India
Royalty Pharma PLC (NASDAQ:RPRX) Declares $0.24 Quarterly Dividend - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $49.07 - Investing.com
Royalty Pharma plc Declares Dividend for the Second Quarter 2026, Payable on June 10, 2026 - marketscreener.com
Royalty Pharma declares $0.235 quarterly dividend - Investing.com
Royalty Pharma Keeps Quarterly Dividend at $0.235 per Share, Payable June 10 to Shareholders of Record as of May 15 - marketscreener.com
Royalty Pharma Declares Second Quarter 2026 Dividend - The Manila Times
Royalty Pharma plc (RPRX) Declares $0.235 Quarterly Dividend; 1.9% Yield - StreetInsider
Royalty Pharma will pay shareholders 23.5 cents a share on June 10 - Stock Titan
Royalty Pharma signs $500M co-development agreement with J&J - MSN
Sumitomo Mitsui Trust Group Inc. Acquires 166,403 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to Announce Q1 2026 Results on May 6 - National Today
TD Cowen lifts PT on Royalty Pharma plc (RPRX) to $50 from $45, here’s why - MSN
Royalty Pharma : Q1 2026 Pre-Quarterly Results Communication - marketscreener.com
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 - The Manila Times
Royalty Pharma schedules May 6 results, 8 a.m. investor webcast - Stock Titan
Foster Victor Wealth Advisors LLC Takes Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma : 2025 Corporate Responsibility Report pdf - marketscreener.com
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive? - Yahoo Finance
Robeco Institutional Asset Management B.V. Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc 8-K Filing – April 2026 Company Information and SEC Disclosure - Minichart
Royalty Pharma funds additional $250M after Phase 3 win for daraxonrasib in metastatic PDAC - TradingView
Royalty Pharma (NASDAQ: RPRX) deepens $2B daraxonrasib royalty and loan pact - Stock Titan
Royalty Pharma plc (RPRX) Proved Resilience in Q1 by Gaining 25.6% - Insider Monkey
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Technical Reactions to RPRX Trends in Macro Strategies - Stock Traders Daily
Trend Review: Does Royalty Pharma plc have high return on assetsForecast Cut & Fast Exit and Entry Trade Guides - baoquankhu1.vn
[ARS] Royalty Pharma plc SEC Filing - Stock Titan
[DEF 14A] Royalty Pharma plc Definitive Proxy Statement - Stock Titan
Today's Analyst Rating Update for Royalty Pharma (RPRX) | RPRX S - GuruFocus
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.95%
자본화:
|
볼륨(24시간):